SI1698630T1 - Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih - Google Patents
Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkihInfo
- Publication number
- SI1698630T1 SI1698630T1 SI200531897T SI200531897T SI1698630T1 SI 1698630 T1 SI1698630 T1 SI 1698630T1 SI 200531897 T SI200531897 T SI 200531897T SI 200531897 T SI200531897 T SI 200531897T SI 1698630 T1 SI1698630 T1 SI 1698630T1
- Authority
- SI
- Slovenia
- Prior art keywords
- rifaximin
- processes
- production
- medicinal preparations
- polymorphous forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
- C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
- C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05004695.2A EP1698630B1 (en) | 2005-03-03 | 2005-03-03 | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1698630T1 true SI1698630T1 (sl) | 2015-01-30 |
Family
ID=34934045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200531897T SI1698630T1 (sl) | 2005-03-03 | 2005-03-03 | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
Country Status (28)
Country | Link |
---|---|
US (9) | US8193196B2 (sl) |
EP (1) | EP1698630B1 (sl) |
JP (2) | JP5737825B2 (sl) |
KR (1) | KR100885755B1 (sl) |
CN (1) | CN1900077B (sl) |
AU (1) | AU2006222312B8 (sl) |
BR (1) | BRPI0608073A8 (sl) |
CA (1) | CA2594789C (sl) |
DK (1) | DK1698630T3 (sl) |
ES (1) | ES2522895T3 (sl) |
HK (1) | HK1096396A1 (sl) |
HR (1) | HRP20070433B1 (sl) |
IL (1) | IL184694A0 (sl) |
MA (1) | MA29345B1 (sl) |
MD (1) | MD4081G2 (sl) |
ME (1) | ME00272B (sl) |
MX (1) | MX2007010742A (sl) |
NO (1) | NO342197B1 (sl) |
NZ (1) | NZ556737A (sl) |
PL (1) | PL1698630T3 (sl) |
PT (1) | PT1698630E (sl) |
RS (1) | RS54570B1 (sl) |
RU (1) | RU2397985C2 (sl) |
SI (1) | SI1698630T1 (sl) |
TN (1) | TNSN07292A1 (sl) |
UA (1) | UA89809C2 (sl) |
WO (1) | WO2006094662A1 (sl) |
ZA (1) | ZA200707397B (sl) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
DK1698630T3 (da) * | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
KR101480732B1 (ko) | 2006-09-22 | 2015-01-21 | 씨아이피엘에이 엘티디. | 리팍시민 |
ITMI20071241A1 (it) * | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
MX2010009389A (es) * | 2008-02-25 | 2010-11-22 | Salix Pharmaceuticals Ltd | Formas de rifaximina y sus usos. |
MX2010009197A (es) | 2008-02-26 | 2010-11-22 | Salix Pharmaceuticals Ltd | Metodos para tratar padecimientos del intestino. |
US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
WO2009137672A1 (en) | 2008-05-07 | 2009-11-12 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
CA2736285C (en) | 2008-09-26 | 2016-08-23 | Aska Pharmaceutical Co., Ltd. | Agent for preventing and/or treating functional gastrointestinal disorder |
HUE048293T2 (hu) | 2008-10-02 | 2020-07-28 | Salix Pharmaceuticals Ltd | Eljárások hepatikus enkefalopátia kezelésére |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
ES2718614T3 (es) | 2008-12-10 | 2019-07-03 | Cipla Ltd | Complejos de rifaximina |
KR20120062897A (ko) | 2009-09-13 | 2012-06-14 | 샐릭스 파마슈티컬스 리미티드 | 과민성 장 증후군(ibs)의 치료방법 |
CN102724960A (zh) | 2009-11-23 | 2012-10-10 | 希普拉有限公司 | 局部泡沫组合物 |
EP2401282B2 (en) | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
WO2011103246A1 (en) | 2010-02-18 | 2011-08-25 | Salix Pharmaceuticals, Ltd. | Methods for treating infection |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
CN101836959A (zh) * | 2010-05-20 | 2010-09-22 | 山东达因海洋生物制药股份有限公司 | 一种制备几乎无苦味利福昔明干混悬剂的方法 |
WO2011156897A2 (en) * | 2010-06-16 | 2011-12-22 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
EA033370B1 (ru) | 2010-07-12 | 2019-10-31 | Salix Pharmaceuticals Ltd | Составы рифаксимина и их применение |
US8759513B2 (en) | 2010-09-13 | 2014-06-24 | Sequent Scientific Limited | Polymorphic form of rifaximin and process for its preparation |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
ES2682965T3 (es) | 2011-02-11 | 2018-09-24 | Salix Pharmaceuticals, Ltd. | Formas de rifaximina y sus usos |
EP2705042A1 (en) | 2011-05-02 | 2014-03-12 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
ITMI20110890A1 (it) * | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
WO2013027227A1 (en) * | 2011-07-20 | 2013-02-28 | Ind-Swift Laboratories Limited | Novel polymorphic form i of rifaximin |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
US20130184302A1 (en) | 2011-11-02 | 2013-07-18 | Enoch Bortey | Methods for treating irritable bowel syndrome (ibs) and infections |
US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014091432A1 (en) | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
AU2014229467A1 (en) | 2013-03-15 | 2015-08-06 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections. |
JP2016516988A (ja) | 2013-03-15 | 2016-06-09 | アルファ ワッセルマン ソシエタ ペル アチオニAlfa Wassermann S.P.A. | 膣感染症を診断するための方法 |
EA032705B1 (ru) | 2013-04-12 | 2019-07-31 | Альфасигма С.П.А. | Способ лечения или предупреждения энтеропатии |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
US9736829B2 (en) * | 2013-10-14 | 2017-08-15 | Qualcomm Incorporated | Downlink control management in an unlicensed or shared spectrum |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
WO2015159275A2 (en) * | 2014-04-19 | 2015-10-22 | Granules India Limited | An improved process for the preparation of rifamycin derivatives |
CA2947962C (en) | 2014-05-04 | 2024-01-16 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
ES2742106T3 (es) | 2014-05-12 | 2020-02-13 | Alfasigma Spa | Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma |
EP2982764A1 (en) | 2014-08-05 | 2016-02-10 | ALFA WASSERMANN S.p.A. | Identification of vaginal bacteria |
WO2017015152A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
TR201909029T4 (tr) | 2016-03-24 | 2019-07-22 | Sandoz Ag | Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler. |
TR201816080T4 (tr) | 2016-03-24 | 2018-11-21 | Sandoz Ag | Ri̇faksi̇mi̇n alfa & delta i̇çeren farmasöti̇k bi̇leşi̇m |
US9988398B2 (en) | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
RS63751B1 (sr) | 2016-09-30 | 2022-12-30 | Salix Pharmaceuticals Inc | Čvrsti disperzioni oblici rifaksimina |
ES2774553T3 (es) | 2017-04-26 | 2020-07-21 | Sandoz Ag | Forma de dosificación oral que incluye rifaximina en forma beta |
IT201700091912A1 (it) * | 2017-08-08 | 2019-02-08 | Biofer Spa | Nuove pirido-imidazo rifamicine |
PL3645539T3 (pl) | 2017-06-26 | 2021-10-25 | Biofer S.P.A. | Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny |
CA3142214A1 (en) | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
CA3151010A1 (en) | 2019-09-24 | 2021-04-01 | Arturo J. Angel | Rifaximin liquid formulations |
US20230116647A1 (en) | 2020-03-24 | 2023-04-13 | Bausch Health Ireland Limited | Methods of treating covid-19 with rifaximin |
CN116018133A (zh) | 2020-06-26 | 2023-04-25 | 博士医疗爱尔兰有限公司 | 靶向释放利福昔明组合物 |
WO2022090490A1 (en) | 2020-10-29 | 2022-05-05 | Bausch Health Ireland Limited | Rifaximin liquid formulations for use in the treatment of sickle cell disease |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2043847A1 (sl) | 1969-05-30 | 1971-02-19 | Takeda Chemical Industries Ltd | |
CH571064A5 (en) | 1973-03-01 | 1975-12-31 | Archifar Ind Chim Trentino | Recovery of rieamycin from broths - by oxidn to an insol form |
US4267274A (en) | 1973-04-26 | 1981-05-12 | Gruppo Lepetit S.P.A. | Streptomyces mediterranei mutant capable of production of rifamycin B |
GB1470426A (en) | 1974-08-30 | 1977-04-14 | Lepetit Spa | Rifamycins |
IT1154655B (it) * | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1199374B (it) * | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
CA1215976A (en) | 1984-05-15 | 1986-12-30 | Vincenzo Cannata | New process for the synthesis of imidazo rifamycins |
IT1199413B (it) | 1984-09-26 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
JP3350861B2 (ja) * | 1990-06-29 | 2002-11-25 | アベンテイス・バルク・ソチエタ・ペル・アチオニ | リファペンチンの純粋の結晶型 |
IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
US6271001B1 (en) | 1995-03-23 | 2001-08-07 | Bio Polymers Pty. Ltd. | Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
KR100467532B1 (ko) | 1996-10-16 | 2005-01-24 | 피에스 팔마큐티칼스 인코퍼레이션 | 프로안토시아니딘 중합체로 된 항-설사 장용피 조제물 |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
EP1330427A1 (en) * | 2000-10-31 | 2003-07-30 | Ciba SC Holding AG | Crystalline forms of venlafaxine hydrochloride |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002089818A1 (en) | 2001-05-03 | 2002-11-14 | Farmigea S.P.A. | Use of sucralfate for the treatment of cervical erosion |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
WO2003101460A1 (fr) | 2002-06-03 | 2003-12-11 | Cac Corporation | Preparations a usage externe pour le traitement de la dermatite |
CZ13908U1 (cs) | 2003-10-08 | 2004-01-05 | Cpn Spol. S R.O. | Kosmetický přípravek s vysokomolekulární antioxidační složkou |
US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20080262024A1 (en) | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
AU2005263958B2 (en) | 2004-07-16 | 2011-04-14 | Cipla Limited | Anti-histaminic composition |
US8003118B2 (en) | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
US20060210492A1 (en) | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Use of rifaximin for treatment and prevention of periodontal conditions |
US20060210483A1 (en) | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITBO20050388A1 (it) | 2005-06-06 | 2006-12-07 | Alfa Wassermann Spa | Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
KR101480732B1 (ko) | 2006-09-22 | 2015-01-21 | 씨아이피엘에이 엘티디. | 리팍시민 |
ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
JP5755878B2 (ja) | 2007-07-06 | 2015-07-29 | ルパン リミテッドLupin Limited | リファキシミンの薬剤組成物 |
EP3714878B1 (en) | 2007-07-06 | 2022-01-19 | Lupin Limited | Pharmaceutical compositions of rifaximin |
WO2009008006A2 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
JP2010259452A (ja) * | 2007-08-21 | 2010-11-18 | Konica Minolta Medical & Graphic Inc | 画像診断支援装置及び画像診断支援方法 |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
WO2009047801A1 (en) | 2007-10-10 | 2009-04-16 | Lupin Limited | Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
MX2010009389A (es) | 2008-02-25 | 2010-11-22 | Salix Pharmaceuticals Ltd | Formas de rifaximina y sus usos. |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
MX2010009197A (es) | 2008-02-26 | 2010-11-22 | Salix Pharmaceuticals Ltd | Metodos para tratar padecimientos del intestino. |
WO2009137672A1 (en) | 2008-05-07 | 2009-11-12 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US20100317681A1 (en) | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
HUE048293T2 (hu) | 2008-10-02 | 2020-07-28 | Salix Pharmaceuticals Ltd | Eljárások hepatikus enkefalopátia kezelésére |
WO2010044093A1 (en) | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
ES2718614T3 (es) | 2008-12-10 | 2019-07-03 | Cipla Ltd | Complejos de rifaximina |
JP5276505B2 (ja) * | 2009-04-06 | 2013-08-28 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
IT1397617B1 (it) | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
CN102625701A (zh) | 2009-06-15 | 2012-08-01 | 萨利克斯药品有限公司 | 对利福昔明***暴露的调节 |
KR20120062897A (ko) | 2009-09-13 | 2012-06-14 | 샐릭스 파마슈티컬스 리미티드 | 과민성 장 증후군(ibs)의 치료방법 |
CA2778181A1 (en) | 2009-10-26 | 2011-05-05 | Thomas Julius Borody | Therapy for enteric infections |
US20120214833A1 (en) | 2009-10-27 | 2012-08-23 | Lupin Limited | Solid dispersion of rifaximin |
WO2011061748A1 (en) | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
US20130202654A1 (en) | 2009-11-23 | 2013-08-08 | Cipla Limited | Topical Foam Composition |
CN102724960A (zh) | 2009-11-23 | 2012-10-10 | 希普拉有限公司 | 局部泡沫组合物 |
EP2401282B2 (en) | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
CN101773465B (zh) | 2010-01-19 | 2012-11-07 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药*** |
WO2011103246A1 (en) | 2010-02-18 | 2011-08-25 | Salix Pharmaceuticals, Ltd. | Methods for treating infection |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
AU2011225810B2 (en) | 2010-03-10 | 2014-11-06 | Lupin Limited | Rifaximin ready-to-use suspension |
EP2380961B1 (en) | 2010-04-23 | 2018-05-23 | The Procter and Gamble Company | Detergent composition |
SG10201507035UA (en) | 2010-06-03 | 2015-10-29 | Salix Pharmaceuticals Ltd | New forms of rifaximin and uses thereof |
WO2011156897A2 (en) | 2010-06-16 | 2011-12-22 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
EA033370B1 (ru) | 2010-07-12 | 2019-10-31 | Salix Pharmaceuticals Ltd | Составы рифаксимина и их применение |
CN103221032A (zh) | 2010-09-13 | 2013-07-24 | 西普拉有限公司 | 药物组合物 |
US8759513B2 (en) | 2010-09-13 | 2014-06-24 | Sequent Scientific Limited | Polymorphic form of rifaximin and process for its preparation |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
WO2012060675A1 (es) | 2010-11-05 | 2012-05-10 | Interquim, S.A. De C.V. | Proceso para la preparación de rifaximina amorfa |
WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
ES2682965T3 (es) | 2011-02-11 | 2018-09-24 | Salix Pharmaceuticals, Ltd. | Formas de rifaximina y sus usos |
EP2705042A1 (en) | 2011-05-02 | 2014-03-12 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
US20130184302A1 (en) | 2011-11-02 | 2013-07-18 | Enoch Bortey | Methods for treating irritable bowel syndrome (ibs) and infections |
CA2861104A1 (en) | 2012-01-25 | 2013-08-01 | Salix Pharmaceuticals, Ltd. | Rifaximin derivative and uses thereof |
JP2013184902A (ja) | 2012-03-06 | 2013-09-19 | Aska Pharmaceutical Co Ltd | リファキシミン含有結晶 |
US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014091432A1 (en) | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
EA032705B1 (ru) | 2013-04-12 | 2019-07-31 | Альфасигма С.П.А. | Способ лечения или предупреждения энтеропатии |
CN105579458A (zh) | 2013-05-17 | 2016-05-11 | 萨利克斯药品公司 | 在正电子发射断层摄影术(pet)扫描中使用利福昔明的方法 |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
ITMI20131307A1 (it) | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
WO2015159275A2 (en) | 2014-04-19 | 2015-10-22 | Granules India Limited | An improved process for the preparation of rifamycin derivatives |
ES2742106T3 (es) | 2014-05-12 | 2020-02-13 | Alfasigma Spa | Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma |
WO2016063289A2 (en) | 2014-10-22 | 2016-04-28 | Strides Arcolab Limited | Pharmaceutical tablet compositions comprising rifaximin |
WO2017021975A1 (en) | 2015-08-06 | 2017-02-09 | Msn Laboratories Private Limited | Process for the preparation of crystalline forms of rifaximin |
TR201816080T4 (tr) | 2016-03-24 | 2018-11-21 | Sandoz Ag | Ri̇faksi̇mi̇n alfa & delta i̇çeren farmasöti̇k bi̇leşi̇m |
TR201909029T4 (tr) | 2016-03-24 | 2019-07-22 | Sandoz Ag | Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler. |
US9988398B2 (en) | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
WO2018158646A1 (en) | 2017-03-02 | 2018-09-07 | Granules India Limited | Rifaximin crystalline form |
WO2018178777A1 (en) | 2017-03-31 | 2018-10-04 | Granules India Limited | Process for the preparation of rifaximin crystalline form |
ES2774553T3 (es) | 2017-04-26 | 2020-07-21 | Sandoz Ag | Forma de dosificación oral que incluye rifaximina en forma beta |
PL3645539T3 (pl) | 2017-06-26 | 2021-10-25 | Biofer S.P.A. | Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny |
-
2005
- 2005-03-03 DK DK05004695.2T patent/DK1698630T3/da active
- 2005-03-03 PL PL05004695T patent/PL1698630T3/pl unknown
- 2005-03-03 EP EP05004695.2A patent/EP1698630B1/en not_active Revoked
- 2005-03-03 PT PT50046952T patent/PT1698630E/pt unknown
- 2005-03-03 SI SI200531897T patent/SI1698630T1/sl unknown
- 2005-03-03 ES ES05004695.2T patent/ES2522895T3/es active Active
- 2005-07-20 CN CN2005100851226A patent/CN1900077B/zh active Active
- 2005-07-28 KR KR1020050068982A patent/KR100885755B1/ko active IP Right Grant
-
2006
- 2006-02-27 JP JP2007557398A patent/JP5737825B2/ja active Active
- 2006-02-27 ZA ZA200707397A patent/ZA200707397B/xx unknown
- 2006-02-27 WO PCT/EP2006/001755 patent/WO2006094662A1/en not_active Application Discontinuation
- 2006-02-27 NZ NZ556737A patent/NZ556737A/en unknown
- 2006-02-27 ME MEP-2008-344A patent/ME00272B/me unknown
- 2006-02-27 BR BRPI0608073A patent/BRPI0608073A8/pt not_active Application Discontinuation
- 2006-02-27 US US11/658,702 patent/US8193196B2/en active Active
- 2006-02-27 MD MDA20070265A patent/MD4081G2/ro active IP Right Grant
- 2006-02-27 AU AU2006222312A patent/AU2006222312B8/en active Active
- 2006-02-27 MX MX2007010742A patent/MX2007010742A/es active IP Right Grant
- 2006-02-27 RU RU2007136430/04A patent/RU2397985C2/ru active
- 2006-02-27 CA CA2594789A patent/CA2594789C/en active Active
- 2006-02-27 RS RS20070364A patent/RS54570B1/en unknown
- 2006-02-27 UA UAA200708880A patent/UA89809C2/uk unknown
-
2007
- 2007-04-03 HK HK07103565.2A patent/HK1096396A1/xx unknown
- 2007-07-18 IL IL184694A patent/IL184694A0/en active IP Right Grant
- 2007-07-24 TN TNP2007000292A patent/TNSN07292A1/en unknown
- 2007-09-20 HR HRP20070433AA patent/HRP20070433B1/hr active IP Right Grant
- 2007-09-26 MA MA30245A patent/MA29345B1/fr unknown
- 2007-10-03 NO NO20074988A patent/NO342197B1/no unknown
-
2012
- 2012-06-04 US US13/488,345 patent/US8518949B2/en active Active
-
2013
- 2013-07-25 US US13/950,642 patent/US8741904B2/en active Active
- 2013-08-01 JP JP2013160684A patent/JP2013216710A/ja not_active Withdrawn
-
2014
- 2014-04-25 US US14/262,612 patent/US9271968B2/en active Active
-
2016
- 2016-01-12 US US14/994,079 patent/US20160362419A1/en not_active Abandoned
-
2017
- 2017-11-13 US US15/811,536 patent/US20180291032A1/en not_active Abandoned
-
2019
- 2019-03-04 US US16/291,900 patent/US10703763B2/en active Active
-
2020
- 2020-05-19 US US16/878,511 patent/US20200277301A1/en not_active Abandoned
-
2021
- 2021-12-28 US US17/563,579 patent/US20220119403A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200707397B (en) | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | |
ZA200401948B (en) | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations. | |
IL225207A (en) | A derivative of multi-ring carbamoylpyridone, its pharmaceutical composition, its use and its preparation | |
SI1928882T1 (sl) | (s)-n-metilnaltrekson, postopek za njega sintezo in njega farmacevtska uporaba | |
IL181012A0 (en) | Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments | |
IL220682A0 (en) | 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor | |
IL173204A0 (en) | Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments | |
IL185484A0 (en) | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents | |
IL179758A0 (en) | Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments | |
EP1731139A4 (en) | PHARMACEUTICAL PREPARATION OF THE S / O TYPE AND MANUFACTURING METHOD THEREFOR | |
IL187235A0 (en) | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament | |
IL216516A0 (en) | Nitrooxy derivatives of glucocorticoids, process for their preparation and use thereof in the manufacture of medicaments | |
ZA200801988B (en) | 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | |
TWI315305B (en) | Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof | |
IL183395A0 (en) | Meta-substituted thiazolidinones, the production thereof and their use as medicaments | |
EP1834624A4 (en) | MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR | |
ZA200700397B (en) | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | |
PL1783105T3 (pl) | Kompozycja zaprawowa, sposób jej wytwarzania i jej zastosowanie | |
IL190596A0 (en) | 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | |
ZA200710146B (en) | New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents | |
IL180894A0 (en) | 1-??-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and processes for the preparation thereof | |
IL186851A0 (en) | Styrylsulfonamides, their manufacture and use as pharmaceutical agents | |
IL189698A0 (en) | Thiomorpholine derivatives and processes for the preparation thereof | |
IL188185A0 (en) | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents | |
ZA200710147B (en) | New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |